Cumulative experimental evidence showed that expression and/or activity of TRPV1 is increased in metabolic syndromes, such as in atherosclerosis (Zhao et al., 2013; Zhao et al., 2016), obesity (Motter and Ahern, 2008; Marshall et al., 2013; Singh et al., 2020; Cocci et al., 2021), hyperlipidemia and NAFLD (Wu et al., 2021), indicating that TRPV1 is involved in the signaling pathway that favors fat accumulation. Here, TRPV1 is linked to metabolic dysfunction-associated steatotic liver disease.